Form 4 for ANIX Anixa Biosciences Inc
Accepted 2023-11-02 00:00:00 ET · period of report 2023-10-31 · accession 0001493152-23-039093 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-02 | 2023-10-31 | ANIX | Catelani Michael | Pres, COO, CFO | A - Grant | $2.69 | +1,117 | 27.8K | +4% | +$3,005 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-31 | A | A | 1,117 | $2.69 | 27,772 | D | — | — | (F2) In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on October 31, 2023. |